BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 29
• 30

• 

  Business

  Allergan and Gedeon Richter Eye Another Indication for Bipolar Depression Drug Cariprazine

  Allergan and its developmental partner Gedeon Richter Ltd. are eying an add-on approval from the U.S. Food and Drug Administration for a depression treatment based on new Phase III data released Tuesday.

  April 4, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Vivaldi CSO Delivers Flu Vaccine Data

  Vivaldi Biosciences announced that its chief scientific officer is delivering a presentation today at the World Vaccine Congress. A new nonclinical trial shows that deltaFLU protected against both distantly drifted and shifted influenza strains, as compared to leading licensed flu vaccines.

  April 4, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Proteostasis Stock Surges on CF Fast Track Designation

  Company shares spiked 12.4 percent higher in premarket trading today after the U.S. Food and Drug Administration (FDA) granted Proteostasis Therapeutics’ triple combination for cystic fibrosis (CF) Fast Track Designation.

  April 4, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  BioCapital

  Drugs That Are Likely to Fall Off the Patent Cliff This Year

  If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.

  April 4, 2018

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Startup Terns Secures Three NASH Assets From Eli Lilly

  The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.

  April 4, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Arsanis Licenses Preclinical E. Col Monoclonal Antibodies

  Shares of Arsanis, Inc. are inching up this afternoon following the company’s announcement of a licensing deal with Austria-based BB100, LLC, a subsidiary of Bravos Biosciences.

  April 4, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Roche Acquires Inception 5 MS Program, Versant Forms New Company

  Building on a four-year-old relationship Roche struck a deal to acquire a regenerative therapy program for multiple sclerosis from Inception Sciences, a drug discovery engine co-founded with Versant Ventures in 2011.

  April 4, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Within Months of Deals with Genentech and Pfizer, Arvinas Raises $55M

  Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.

  April 4, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Eli Lilly’s Cyramza Succeeds in Phase III Trial

  Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.

  April 4, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Eli Lilly Plunks Down $63M Upfront in Deal With Startup Sigilon

  Less than one year after it launched Cambridge, Mass.-based startup Sigilon Therapeutics struck a collaboration deal with Eli Lilly to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.

  April 4, 2018

   · 

  2 min read

   · 

  Alex Keown